Objective-Cingulin is a cytoplasmic component of tight junctions. Although modulation of cingulin levels in cultured epithelial model systems has no significant effect on barrier function, evidence from cingulin knockout mice suggests that cingulin may be involved in the regulation of the behavior of epithelial or endothelial cells. Here, we investigate the role of cingulin in the barrier function of endothelial cells. Approach and Results-We show that cingulin is expressed in human endothelial cells of the skin, brain, and lung in vivo and in vitro. Endothelial cingulin colocalizes and coimmunoprecipitates with the tight junction proteins zonula occludens-1 and guanine nucleotide exchange factor-H1. Cingulin overexpression in human umbilical vein endothelial cell induces tight junction formation, increases transendothelial electric resistance, and strengthens barrier function for low and high molecular weight tracers. In contrast, cultured endothelial cells lacking cingulin are more permeable for low molecular weight tracers. In cingulin knockout mice, neurons of the area postrema and Purkinje cells show an increased uptake of small molecular weight tracers indicating decreased barrier function at these sites.
T ight junctions (TJs) are critical for the establishment and maintenance of barriers between different body compartments in vertebrate epithelia and endothelia. At the molecular level, TJs comprise transmembrane proteins of different classes, 1 such as 4-pass-membrane proteins (occludin, claudins, tricellulin, and marvelD3), Ig-like junctional adhesion molecules and others (Bves and angulins); cytoplasmic scaffolding proteins, 2 including the zonula occludens (ZO) proteins (ZO-1, ZO-2, and ZO-3), cingulin (CGN), and paracingulin; signaling proteins, including Rho GTPases, their activators (guanine nucleotide exchange factors [GEFs] ) and inhibitors (GTPaseactivating proteins), as well as kinases and phosphatases. [3] [4] [5] See accompanying editorial on page 584
TJs are associated and are functionally interacting with adherens junctions in both epithelial and endothelial cells. [6] [7] [8] [9] In spite of the importance of endothelial TJ in the formation of blood-tissue barriers and their involvement in pathogenic processes, such as edema formation, the molecular organization of endothelial TJ has been poorly characterized. Endothelial cells express a specific claudin isoform, claudin-5, which when knocked out in mice results in increased vascular permeability in the brain. 10 However, little is known about the role of specific components of the TJ cytoplasmic plaque in the regulation of endothelial barrier function. 11 Cingulin is a specific component of the cytoplasmic plaque of epithelial TJ, 12 which functions as a scaffold for Rho-GEFs (GEF-H1 and p114RhoGEF) and for MgcRacGAP in different cultured epithelial cells. [13] [14] [15] [16] By recruiting and inactivating GEF-H1 to TJ, cingulin downregulates RhoA activation in confluent cells. Cingulin-depleted cells show increased RhoA activation, and RhoA-dependent increases in claudin-2 expression and cell proliferation. 14 An aggravated response of cingulin knockout in mice to the ulcer-inducing drug cysteamine suggests that cingulin in epithelial, submucosal, or endothelial cells may be involved in acute duodenal injury. 17 The expression of cingulin in endothelial cells has been poorly characterized because early studies showed a low abundance of cingulin in endothelial cells when compared with epithelia. 18, 19 However, the recently characterized role of GEF-H1 in regulating endothelial permeability 20, 21 raises the possibility that cingulin is a key regulator of endothelial barrier function.
Here, we studied the expression and molecular environment of cingulin in different types of endothelial cells. Furthermore, we characterized the effects of exogenous cingulin expression or deletion of the cingulin head domain on the expression of claudin-5 and endothelial barrier function and analyzed barrier function in cingulin-deficient mice. The results indicate that expression levels of cingulin contribute to regulating endothelial barrier function.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Cingulin Is Localized at Human Endothelial TJ In Situ
We analyzed the expression of cingulin in different vascular beds by immunohistochemistry. Endothelial cells of large and small-sized veins and arteries in human skin, lung, and brain tissues stained positive with anticingulin antibodies ( Figure 1A ). By immunofluorescence, cingulin labeling was detected in close proximity of VE-cadherin labeling with a Pearson correlation coefficient of 0.11, but was colocalizing with ZO-1 labeling resulting in a Pearson correlation coefficient of 0.31 ( Figure 1B) , supporting the notion that cingulin is associated with TJ of endothelial cells. 22 Analysis of mRNA expression levels of cingulin relative to VE-cadherin in different tissues and vessels showed that cingulin expression was detectable in the brain, the vena cava, and the aorta, whereas no expression was detected in muscle and heart ( Figure 1C ).
Cingulin Is Expressed in Cultured Endothelial Cells and Forms a Complex With ZO-1 and GEF-H1
To further test cingulin expression in cultured endothelial cells, we analyzed human umbilical vein endothelial cells (HUVEC), human dermal microvascular endothelial cells (DMEC), lymphatic endothelial cells, human pulmonary microvascular endothelial cells from the lung and-as positive control-human bronchial epithelial cells by immunofluorescence, quantitative reverse transcription polymerase chain reaction, and immunoblotting. Human bronchial epithelial cell displayed intense cingulin labeling at junctions, which clearly colocalized with ZO- 1 pulmonary microvascular endothelial cells showed stainings with anticingulin antibody in cells culture, albeit less than human bronchial epithelial cells and it colocalized with ZO-1 ( Figure 2A ). In lymphatic endothelial cells, ZO-1 was clearly detectable at cell junctions, but cingulin staining was absent. Cingulin expression levels were confirmed by quantitative reverse transcription polymerase chain reaction ( Figure 2B ) and Western blotting ( Figure 2C ). Fibroblasts served as negative controls (negative for VE-cadherin and cingulin). Human bronchial epithelial cells (negative for VE-cadherin) served as a positive control for cingulin. To examine the solubility properties of cingulin, we performed sequential steps of extraction and protein solubilization. After cell lysis in Tris buffer, supernatants were collected (first step) and pellets were lysed in radioimmunoprecipitation assay buffer (RIPA) buffer. Again, supernatants were taken (second step) and pellets were lysed in Laemmli buffer (third step) followed by blotting of lysates from all steps. The 140-kDa protein cingulin was detectable in all fractions, in both, DMEC and human pulmonary microvascular endothelial cells, although less than in the positive control, bronchial epithelial cells ( Figure 2C ). Of note, a significant portion of cingulin still remained in the third fraction, indicating a strong association with the actin cytoskeleton in endothelial cells. By contrast, the adherens junction marker VE-cadherin was mainly seen in the membrane/cytosol fraction. These results indicate that cingulin exists in both soluble and insoluble (eg, cytoskeleton associated) fractions in cultured endothelial cells. In HUVEC, although cingulin mRNA was expressed (using primers at the transition between head and rod domain), full-length protein was absent (using an antirod domain antibody). Instead, we detected a protein of 40 kDa, which could represent a processed protein.
To probe the molecular environment of cingulin in endothelial cells, we performed immunoprecipitation with anti-ZO-1 antibodies. Analysis of immunoprecipitates revealed GEF-H1 and cingulin in a complex with ZO-1 in endothelium ( Figure 2D ), similar to the TJ complex seen in epithelial cells. [23] [24] [25] 
Exogenous Cingulin Expression in Endothelial Cells Reduces Claudin-5 Expression and Induces the Formation of TJ
To study the role of cingulin in modulating barrier function in cultured endothelial cells, we overexpressed cingulin constructs bearing a green fluorescent protein (GFP)-tag fused to the head-and a myc-tag fused to the tail-domain in HUVEC . Previous experiments demonstrated that GFPtagged cingulin behaves like untagged cingulin. 16, 26, 27 First, because modulation of cingulin levels is known to affect the expression of claudin family proteins, we assessed the impact of cingulin overexpression on the expression of the endothelial-specific claudin, claudin-5. Exogenous expression of cingulin reduced claudin-5 protein and mRNA expression levels by 50% in HUVEC and by 38% in DMEC ( Figure 3A ; Figure IA and IB in the online-only Data Supplement). To confirm these findings on a single-cell level, HUVEC overexpressing cingulin were mixed with nontransfected HUVEC (1:1) and grown to confluence. Cingulin-overexpressing cells ( Figure 3C , green) showed lower levels of claudin-5 (red), as indicated by the weaker immunofluorescent signal. In addition, cingulin overexpression induced TJ formation in HUVEC as assessed by electron microscopy ( Figure 3B ). The number of induced TJ in neighboring HUVEC membranes was quantified for a total distance of 16 μm per sample.
Cingulin Overexpression Reduces Proliferation and Improves Endothelial Barrier Function
Cingulin overexpression reduced proliferation in HUVEC and DMEC as assessed by measurement of double-stranded DNA content ( Figure 4A ).To measure endothelial barrier function, transendothelial electric resistance of HUVEC monolayers was measured continuously >14 days. Resistance at high frequencies (32 000 Hz) measures both transcellular (across cell bodies) and paracellular (through junctions) permeability. The lower signal at 32 000 Hz seen in cingulin-overexpressing cells ( Figure 4B ) mainly reflects lower cell numbers (which is based on reduced proliferation; Figure 4A ). By contrast, resistance at 250 Hz, which measures paracellular resistance, was significantly higher in cingulin-overexpressing cells than in controls ( Figure 4C ), indicating stronger junctional cohesion.
In addition, measuring permeability for fluorescent 376 Da and 70 000 Da tracers in a transwell assay revealed a significantly reduced permeability for both fluorescent tracers in HUVEC-overexpressing cingulin ( Figure 4D ). The effect of cingulin was less pronounced in DMEC and reached significance only for the 376-Da tracer ( Figure IC in the onlineonly Data Supplement). This could be because of the fact that endogenous levels of cingulin in DMEC cells are higher, and therefore the impact of cingulin overexpression is less strong ( Figure 2C ).
Mutant Cingulin Mice Display Altered Location of GEFs and a Defective Blood-Brain Barrier
To further investigate the role of cingulin in vivo, we used cingulin knockout mice (CGN −/− ), carrying a deletion of the exon coding for the cingulin head domain. In these mice, truncated cingulin is not relevant for its junctional function 17 ( Figure 5A and 5D ). The deletion of the head domain was confirmed by Western blotting, and quantitative reverse transcription polymerase chain reaction ( Figure 5B and 5C) and caused increased expression of the rod domain. Potentially, this is a compensatory effect. Despite the absence of cingulin from cellular junctions ( Figure 5D ) CGN −/− mice are able to form morphologically intact TJ, as assessed by electron microscopy (Figure 5E ). No significant difference in mRNA expression of indicated junctional proteins was found in lysates derived from the thoracic aorta ( Figure 5C ). Moreover, CGN −/− mice are born in mendelian ratios and do not have a survival problem.
Because a more subtle and context-driven mechanism through which cingulin may affect endothelial barrier function could be through modulation of the recruitment of GEFs that regulate RhoA activity, we investigated the expression and Figure 5 . In the absence of the cingulin (CGN) head domain, the rod domain is unable to localize to the membrane. A, Schematic image of the CGN gene in mice targeted for knockout. Deleting exon 1 leads to a truncated version of CGN missing the head domain, a potential in frame transcription start is present at an ATG in exon 4. B, Western blots of lysates from the aorta or from lungs of CGN −/− mice or wildtype (WT) littermates. The full-length CGN is marked by arrows, the truncated rod domain is marked by asterisks at a size predicted from gene analysis. C, mRNA expression of indicated proteins is from aorta lysates of CGN −/− mice or of WT littermates; values are expressed as fold change relative to WT littermates, mean±SD. n=12. D, Immunofluorescence imaging of lung epithelium reveals that truncated cingulin does not localize to junctions. E, Electron micrograph of a blood vessel in the lung of a CGN −/− mouse shows neighboring endothelial cell membranes with morphologically intact zonula occludens (ZO), scale bar=100 nm. localization of GEF-H1 and p114RhoGEF in tissues of wildtype and CGN −/− mice. In wild-type mice, phosphorylated GEF-H1 and p114RhoGEF were seen at both, junctional and cytoplasmic locations. By contrast, in CGN −/− mice, pGEF-H1 and p114RhoGEF were undetectable at endothelial surfaces ( Figure 6A ). Next, we assessed blood-brain barrier function in CGN −/− mice and wild-type littermates by analyzing biotin extravasation after injection into the tail vein. At sites with a known reduced blood-brain barrier, 28 biotin uptake was significantly increased. Numbers of biotin-positive Purkinje cells ( Figure 6B ) and numbers of biotin-positive neurons in the area postrema (data not shown) were significantly increased in CGN −/− mice when compared with wild-type littermates. To confirm the defective barrier function of endothelial cells lacking junctional cingulin, we isolated endothelial cells from mice, and assessed the mRNA expression of junctional proteins, as well as their barrier function. The expression of claudin-5 was higher in endothelial cells lacking cingulin, but was not significant because of high variations between isolations from individual donors ( Figure 6C) . Proliferation rates were not changed ( Figure II in the online-only Data Supplement). Yet, the permeability for small molecular weight tracer seen in cingulin-deficient endothelial cells was significantly increased when compared with controls ( Figure 6D ).
Discussion
Here, we describe the expression and localization of cingulin in vascular beds. Furthermore, we provide evidence for a role of cingulin in the modulation of barrier function in endothelia. Cingulin localizes into the TJ complex and binds to ZO-1 and GEF-H1 and a significant portion of cingulin is linked to the cytoskeleton. Moreover, cingulin overexpression decreases cell proliferation. These findings in endothelium are consistent with observation in epithelial cells, where cingulin localizes to TJ, 23, 24 and cingulin depletion results in increased cell proliferation, through a GEF-H1 and RhoAdependent mechanism. 14, 29 In epithelial cells, the increase in cellular cingulin content in differentiating cells is one of many regulatory mechanisms that control epithelial tissue biogenesis. 30, 31 It is a common feature of TJ components to inhibit cell proliferation. 32, 33 Endothelium undergoes growth arrest on cell-cell contact formation. Cingulin may contribute to this process to maintain an endothelial monolayer lining vascular surfaces. Our results are controversial on the role of cingulin in controlling the composition of TJ proteins. In cell culture, overexpression of cingulin downregulates, deletion upregulates claudin-5 expression in endothelium by a yet unknown mechanism. Cingulin was previously shown to regulate the expression of claudin-2 in renal epithelial cells through RhoA-and GATA-4-dependent mechanisms. 14, 34 However, in CGN −/− mice, in vivo, claudin-5 was unchanged, indicating additional regulatory components. Importantly, the presence or absence of cingulin in vitro and in vivo alters endothelial permeability. In this respect, endothelium differs from epithelium, the latter showing no barrier defect on cingulin depletion. 14, 26 This may, in part, be explained by the abundance of cingulin in epithelium when compared with endothelium (10-100-fold difference based on mRNA levels). Given a ≈90% reduction of cingulin by a small hairpin RNA-based approach, the remaining cingulin in epithelium seems still sufficient to maintain TJ function.
In cell culture, HUVEC are unable to form sophisticated TJ. 11 We show that overexpression of cingulin in HUVEC restores TJ formation similar to the improvement with S1P 35 or astrocyte conditioned media. 36 This contrasts the situation in vivo. Endothelial cells in the CGN −/− mouse and in human umbilical cords 37 show morphologically intact TJ indicating additional, yet unknown regulatory mechanisms in vivo.
We speculate that one major mechanism through which cingulin regulates endothelial barrier function is through its role in modulating the activity of junctional RhoGTPases, via binding to GEFs and GTPase-activating proteins. 38 Indeed, our results provide evidence that cingulin is a scaffold protein for GEF-H1 and p114RhoGEF in endothelial cells because junctional labeling for these GEFs was lost in CGN −/− tissues. The emerging roles of GEF-H1 and p114RhoGEF in regulating endothelial barrier function [20] [21] [22] support the idea of a mechanism based on the regulation of Rho GTPases.
Evidence supporting a role of cingulin in the regulation of barrier function of endothelial cells also comes from studies showing that a peptide based on the N-terminal sequence of cingulin increases barrier function and reduces edema formation in an animal burn model 39 and in a lung transplantation model. 40 This is directly shown in our CGN −/− mice. The truncated cingulin protein is unable to localize to the TJ resulting in an increased uptake of biotin in brain neurons at sites with a known reduced blood-brain barrier. 28 In peripheral organs under physiological conditions, endothelial barrier function seems independent of cingulin. However, based on previous data showing increased ulcer formation in cingulin-deficient mice, 17 we postulate that cingulin may play a role in stress conditions. Additional studies will aim to investigate the role of cingulin in disease models associated with vascular leak syndromes, such as acute lung injury.
In conclusion, cingulin participates in endothelial barrier function and understanding its role in creating tight barriers may open the door to develop new strategies for the treatment of vascular leak syndromes in the brain and potentially also in peripheral organs.
We show that cingulin is implicated in the regulation of endothelial barrier function. Knowledge of the molecules regulating endothelial barrier function is crucial to develop therapies for diseases involving vascular leak.
Significance
